For more than 75 years, Grifols has been improving the health and well-being of people. Our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. The Grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine.
Grifols has three business divisions:
Bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. Diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. Research novel technologies to further improve treatment outcomes and laboratory efficiency. Hospital specializes in non-biological pharmaceutical products. This division supplies hospitals with a wide range of pharmaceutical products and medical devices for use in hospital pharmacy, automated compounding, clinical nutrition and fluid therapy.
Market capitalization (25-Jul-2017)
Closing share price (25-Jul-2017)